Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Apr;34(1):1-13.
doi: 10.1007/BF00666486.

Therapy of small breast cancer--four-year results of a prospective non-randomized study. German Breast Cancer Study Group (GBSG)

No authors listed
Clinical Trial

Therapy of small breast cancer--four-year results of a prospective non-randomized study. German Breast Cancer Study Group (GBSG)

No authors listed. Breast Cancer Res Treat. 1995 Apr.

Abstract

Background: In the early 1980s breast preservation was a rarely applied therapeutic modality in the primary treatment of breast cancer in the Federal Republic of Germany. Reports coming from retrospective studies as well as preliminary results from randomized trials made it desirable to introduce breast preservation in the form of a controlled clinical trial.

Study design: In stage pT1 N0 M0 breast cancer, mastectomy as the standard treatment was to be compared with radiotherapy of the remaining breast tissue. The study design originally planned as a randomized trial had to be changed into a prospective observation study due to the low randomization rate. Univeriate analysis of prognostic variables was the first step to a valid treatment comparison. Those factors determined as being significant were included together with the treatment effects in a multivariate analysis. A high therapeutic standard was guaranteed by quality control.

Results: 1036 out of 1119 recruited patients are evaluable. After a median follow-up of 48 months the following preliminary results can be reported. With the exception of death without recurrence from breast cancer, the 143 events are evenly distributed among the two treatment groups. Locoregional recurrence of the whole patient population was 5%. Out of all prognostic factors examined only tumor size and grading are significant in regard to recurrent disease. Recurrence-free survival decreased in cases with 'uncertain' tumor margins, whereas the width of the margin had no influence on recurrent disease. There was no significant difference in quality of life between the two treatment groups.

Conclusions: The four-year results of this study are in accordance with those of other breast preservation trials: There is no significant difference between the two treatment groups in the occurrence of locoregional failure. Incomplete tumorectomy has a negative influence on recurrence. Quality of life seems more dependent on the acceptance of the therapy by the patient than on the therapeutic modality itself. Breast preservation can also be performed appropriately in smaller institutions if the therapeutic standard is guaranteed by quality control.

PubMed Disclaimer

References

    1. Cancer. 1978 Oct;42(4):2045-53 - PubMed
    1. J Natl Cancer Inst Monogr. 1992;(11):27-32 - PubMed
    1. J Natl Cancer Inst. 1990 Jun 20;82(12):1006-15 - PubMed
    1. N Engl J Med. 1990 Apr 12;322(15):1045-53 - PubMed
    1. Int J Radiat Oncol Biol Phys. 1992;23(5):907-14 - PubMed

LinkOut - more resources